Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
42 participants
OBSERVATIONAL
2020-10-18
2022-01-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection
NCT04584671
Persistent Dyspnea in Post COVID_19 and Pulmonary Function
NCT05228678
Respiratory Infection Monitoring
NCT04362631
Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)
NCT05374577
Impact of COVID19 on Asthma Patients in Spain
NCT05064501
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
healthy COVID-19+
Individuals who recently recovered from COVID-19 and who have no history of lung disease
V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
asthmatic COVID-19+
Individuals who recently recovered from COVID-19 and who have asthma
V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
healthy COVID-19-
Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease
V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
asthmatic COVID-19-
Individuals who have not been diagnosed with COVID-19 and who have asthma
V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and females ≥ 18 years of age
* Individuals able and willing to provide written informed consent
* Individuals able and willing to comply with the study protocol
For participants with asthma:
* Individuals with physician confirmed asthma (12% bronchodilator reversibility or PC20 methacholine less than 8mg/ml)
* Individuals treated with inhaled corticosteroids, oral corticosteroids and/or anti-T2 biologics
For participants who recently recovered from covid-19:
* Individuals previously diagnosed with covid-19 confirmed by FLOQswab test
* Individuals who recently (≤4-weeks) recovered from covid-19
Exclusion Criteria
* Males and females \< 18 years of age
* Individuals who are unable to read and/or understand English
* Individuals who are pregnant or breastfeeding
* Individuals who currently smoke or are an ex-smoker with ≥10 pack-year smoking history
* Individuals who in the opinion of the investigator, are mentally or legally incapacitated, preventing informed consent from being obtained
* Individuals who are unable to complete one or more study manoeuvres
For participants with no history of lung disease:
* Individuals with a history of respiratory infection or disease
For participants who have not been diagnosed with covid-19:
* Individuals who have previously had covid-19 confirmed by FLOQswab test
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McMaster University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarah Svenningsen, PhD
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIRH002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.